NASDAQ:RCKTRocket Pharmaceuticals Stock Price, Forecast & News

$19.78

-0.24 (-1.20 %)

(As of 05/28/2020 10:41 AM ET)

Add

Compare

Today's Range

$19.74

Now: $19.78▼

$20.29

50-Day Range

$14.71

MA: $17.21▼

$20.28

52-Week Range

$9.01

Now: $19.78▼

$27.59

Volume3,027 shs

Average Volume350,353 shs

Market Capitalization$1.09 billion

P/E RatioN/A

Dividend YieldN/A

Beta2.27

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. In addition, the company has an adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in New York, New York.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Rocket Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $38.67, Rocket Pharmaceuticals has a potential upside of 95.5% from its current price of $19.78.
Amount of Analyst Coverage
Rocket Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Rocket Pharmaceuticals has received 297 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Rocket Pharmaceuticals has received 216 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Rocket Pharmaceuticals has received 57.89% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Rocket Pharmaceuticals and other stocks. Vote “Outperform” if you believe RCKT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RCKT will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Rocket Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Rocket Pharmaceuticals does not have a long track record of dividend growth.

5.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rocket Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,500.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
41.40% of the stock of Rocket Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
96.70% of the stock of Rocket Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Rocket Pharmaceuticals are expected to grow in the coming year, from ($2.03) to ($1.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Rocket Pharmaceuticals is -12.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Rocket Pharmaceuticals is -12.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Rocket Pharmaceuticals has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.41 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:RCKT

Previous Symbol

CUSIPN/A

CIK1281895

Webwww.rocketpharma.com

Phone646-440-9100

Debt

Debt-to-Equity Ratio0.23

Current Ratio13.25

Quick Ratio13.25

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$5.19 per share

Price / Book3.81

Profitability

EPS (Most Recent Fiscal Year)($1.58)

Net Income$-77,270,000.00

Net MarginsN/A

Return on Equity-30.73%

Return on Assets-24.38%

Miscellaneous

Employees33

Outstanding Shares55,160,000

Market Cap$1.09 billion

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive RCKT News and Ratings via Email

Sign-up to receive the latest news and ratings for RCKT and its competitors with MarketBeat's FREE daily newsletter.

Rocket Pharmaceuticals (NASDAQ:RCKT) Frequently Asked Questions

How has Rocket Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Rocket Pharmaceuticals' stock was trading at $15.99 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, RCKT stock has increased by 23.7% and is now trading at $19.78. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Rocket Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rocket Pharmaceuticals.

When is Rocket Pharmaceuticals' next earnings date?

Rocket Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Rocket Pharmaceuticals.

How were Rocket Pharmaceuticals' earnings last quarter?

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) announced its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($0.45) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.48) by $0.03. View Rocket Pharmaceuticals' earnings history.

What price target have analysts set for RCKT?

6 equities research analysts have issued 12-month price objectives for Rocket Pharmaceuticals' stock. Their forecasts range from $33.00 to $42.00. On average, they expect Rocket Pharmaceuticals' share price to reach $38.67 in the next twelve months. This suggests a possible upside of 95.5% from the stock's current price. View analysts' price targets for Rocket Pharmaceuticals.

Has Rocket Pharmaceuticals been receiving favorable news coverage?

Media headlines about RCKT stock have been trending somewhat negative recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Rocket Pharmaceuticals earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutRocket Pharmaceuticals.

Who are some of Rocket Pharmaceuticals' key competitors?

Some companies that are related to Rocket Pharmaceuticals include Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), PPD (SDGR), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Zai Lab (ZLAB), Evotec (EVTCY), ChemoCentryx (CCXI), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Allakos (ALLK), Biohaven Pharmaceutical (BHVN) and Arrowhead Pharmaceuticals (ARWR). View all competitors.

What other stocks do shareholders of Rocket Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Alibaba Group (BABA), Pfizer (PFE), Walt Disney (DIS), NVIDIA (NVDA), SCYNEXIS (SCYX), Amarin (AMRN), Bristol-Myers Squibb (BMY), Crispr Therapeutics (CRSP) and Cisco Systems (CSCO).

Who are Rocket Pharmaceuticals' key executives?

Rocket Pharmaceuticals' management team includes the following people:

Mr. Gaurav Shah, CEO, Pres & Director (Age 44)
Mr. John C. Militello, Controller (Age 46)
Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA, COO & Head of Devel. (Age 39)
Dr. Claudine Prowse Ph.D., Sr. VP of Corp. Strategy & IRO
Mr. Jonathan Schwartz, Chief Medical Officer (Age 55)

What is Rocket Pharmaceuticals' stock symbol?

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Who are Rocket Pharmaceuticals' major shareholders?

Rocket Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (4.91%), Perceptive Advisors LLC (3.97%), Wellington Management Group LLP (3.04%), Cormorant Asset Management LP (2.84%), Lord Abbett & CO. LLC (2.74%) and State Street Corp (1.75%). Company insiders that own Rocket Pharmaceuticals stock include David P Southwell, Gaurav Shah, Kinnari Patel, Naveen Yalamanchi and Rtw Investments, Lp. View institutional ownership trends for Rocket Pharmaceuticals.

Which major investors are selling Rocket Pharmaceuticals stock?

RCKT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Cormorant Asset Management LP, Wellington Management Group LLP, Franklin Resources Inc., Blair William & Co. IL, Perceptive Advisors LLC, and Ghost Tree Capital LLC. View insider buying and selling activity for Rocket Pharmaceuticals.

Which major investors are buying Rocket Pharmaceuticals stock?

RCKT stock was acquired by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Lord Abbett & CO. LLC, Deutsche Bank AG, Frazier Management LLC, Nuveen Asset Management LLC, Federated Hermes Inc., JPMorgan Chase & Co., and Healthcare of Ontario Pension Plan Trust Fund. Company insiders that have bought Rocket Pharmaceuticals stock in the last two years include Kinnari Patel, and Rtw Investments, Lp. View insider buying and selling activity for Rocket Pharmaceuticals.

How do I buy shares of Rocket Pharmaceuticals?

Shares of RCKT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rocket Pharmaceuticals' stock price today?

One share of RCKT stock can currently be purchased for approximately $19.78.

How big of a company is Rocket Pharmaceuticals?

Rocket Pharmaceuticals has a market capitalization of $1.09 billion. The biotechnology company earns $-77,270,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis. Rocket Pharmaceuticals employs 33 workers across the globe.

What is Rocket Pharmaceuticals' official website?

The official website for Rocket Pharmaceuticals is www.rocketpharma.com.

How can I contact Rocket Pharmaceuticals?

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The biotechnology company can be reached via phone at 646-440-9100 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff